ANIK logo

ANIKA THERAPEUTICS INC

ANIKNASDAQ
πŸ† #3310 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track ANIK
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$288M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-2.5%
Declining
πŸ“ŠGross Margin
62.2%
High
πŸ’΅FCF Margin
7.4%
Moderate
βš–οΈP/S Ratio
2.4x
Cheap
Otter Score
84
Strong
No chart data available for ANIK.

Trading Snapshot

Day Range
β€”
52-Week Range
$9.01 – $22.88
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
13.4M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$113M
Last Q Revenue
$33M
P/E Ratio
β€”
P/S Ratio
2.4x
EPS (TTM)
$-0.27
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.4%
ANIK logo

ANIKA THERAPEUTICS INC

ANIK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$113Mβ–Ό βˆ’5.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
56.6%β–Ό βˆ’10.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$11Mβ–² +116.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$4Mβ–Ό βˆ’287.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
14.7Mβ–Ό βˆ’0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$31Mβ–² +$2M YoY
StockOtter Β· stockotter.space

About ANIKA THERAPEUTICS INC

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100
Analyst data unavailable.

Latest News & Updates

News unavailable.